¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º .B:ZyTI  
iBSM \ n  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ @N4_){s*  
tOiz tYu  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) R| ?Q&F_$  
$oBs%.Jp  
1. ICAM-1 ~)U50. CH  
 J=` 8  
2. interleukin 12(IL-12) <fvu) f  
qVC+q8  
3. tumor infiltrating lymphocyte $hhXsu=  
7;EDU  
4. TCR/CD3 complex Q,3kaR@O  
2{79,Js0  
5. hematopoietin receptor family s2O()u-  
Msqqjhoy  
6. individual idiotype(IdI) !mlfG "FE  
<_Yd N)x  
7. integrin gi!_Nz  
#X-C~*|>j  
8. colony-stimulatory factor (CSF) 5#.m 'a)  
pJHdY)Cz  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© |T<aWZb^=  
Kv@P Uzu  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? $s7U |F,I  
 =yod  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ o +$v0vg%T  
BN9e S   
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ~0PzRS^o  
U"Gx Xrl  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ 1M`E.Ztw*  
S^%3Vf}  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) }g+kU1y  
cO5F=ZxR  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ Q:P)g#suc  
kK75(x  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) XM\\ Imw  
og";mC  
3. immunoglobulin superfamily (IgSF) 89M'klZ   
Au2?f~#Fv  
4. selectin UBL{3s^"  
Wc@ ,#v  
5. anti-idiotypic antibody (¦ÁId) 6Q:Wo)^!  
/si<Fp)z  
6. major histocompatibility complex(MHC) ]Za[]E8MD  
3wfcGQn|sD  
7. immunotolerance T`e`nQ0nn  
O|t>.<T?  
8. biological reponse modifier(BRM) (xo`*Q,+  
1@Jp3wW  
9. immune reponse gene (Ir gene) $IQPB_:  
{@2+oOuYfN  
10. reshaped antibody (or reconstituted antibody) o9}\vN0F  
%?[gBf[y  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© AO5&Y.A#  
;B@#,6t/  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ 8gavcsVE[  
zg ,=A?  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? +.~K=.O)  
f +9eB  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ (l %?YME  
`<g]p-=":  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? |fKT@2(  
9}QIqH\p  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ Lk|`\I T  
-Kg.w*\H7/  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? EmaS/]X[  
+ZbNSN=  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ (W#CDw<ja  
CmXLD} L_x  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ '4M{Xn}@  
W!$U{=  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? k6"(\d9o  
MhA4C 8  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ "Bwz Fh  
\)5mO 8w  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: LpY{<:y  
3\4e{3$  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ZxSnqbyA*  
Q3%]  
ÃâÒßѧ Z$INmo6  
vE,^K6q0`  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© @]IRB1X  
k62s|VeU  
1. CD8 }F0<8L6%  
ML'y`S  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) d :|x e:  
1OExa<Zq  
3. immunoglobulin fold(Ig fold) '*L6@e#U  
4v/MZ:%C`  
4. cadherin (Ca-dependent cell adhesion moleculers) t O.5  
vGlVr.)  
5. idiotype-anti-idiotypic antibody immune network theory T0dD:sN  
'W hJ}Uo\  
6. HLA class II antigen C{m%]jKH  
{|>Wwa2e  
7. complementarity-determining region (CDR) wH!$TAZ:Yw  
M1WD^?tKQ.  
8. perforin(or pore-forming protein ,PFP) ]w>o=<?b  
X-nC2[tu'W  
9. high affinity IL-2 receptor jr0j0$BF  
FHU6o910  
10. artificial active immunization ";=!PL  
-GFZFi  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© /a^ R$RHl'  
8O]`3oa>  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ'42$O  
}r@dZ Bp:  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 Bz_'>6w  
f/O6~I&g  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ SC~k4&xy  
+`GtZnt#  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ :CE4< {V  
=${.*,o  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ 7C7.}U  
uRko[W(  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? ?yS1|CF%&y  
\PE;R.v_:  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ @/<UhnI  
(|^m9v0:  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ aq$ hE-{28  
A! bG2{r  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ).5 X  
k B> F(^  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ 4uIYX  
h) Wp  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© qazA,|L!  
#; ?3k uq(  
1. immunoglobulin gene rearrangement GjhTF|  
3^y(@XFt  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) G7CeWfS  
 p +i 1sY  
3. flow cytometry(FCM) W r/-{Wt  
yQ2=d5'V`  
4. carrier effect 2 kDsIEA  
B'}?cG]  
5. positive selection of T lymphocytes in thymus f4f2xe7\Q  
{.:$F3T  
6. mouse TH1(Th1) and TH2(Th2) subsets @V*dF|# /  
KG'i#(u[  
7. perforin (pore-forming protein ,PFP) 3 ~v 17  
5BhR4+1J  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) o <q*3L5  
H -kX-7C  
9. SH-2(src-homology region 2) & N7ji  
VPUVPq~ &  
10. Ab2¦Â (internal image) _VrY7Mz:r  
n<ZPWlJ  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© II\&)_S.4  
S0,\{j  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? =gB5JB<}2  
rJ!cma  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? ]O@$}B];)  
7>E.0DP  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ]b4WfIu  
Cx7-I0!  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ ZitM<Qi&y  
ZaFt4#  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦ÓᣠD|;O9iks#  
.G0 N+)  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) $]v}X},,  
1vj/6L  
ÃâÒßѧרҵ£º ,WT>"9+  
{0zn~+  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ V`V\/s gj  
rd%%NnT"  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? Zi!Ta"}8  
o96C^y{~S  
´«È¾²¡Ñ§×¨Òµ£º ($[wCHU`!  
V$^jlWdR  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ NxT"A)u  
Rj8%% G-pt  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ C8N)!5(A  
|c_qq Bd  
Ïû»¯×¨Òµ£º vF$i"^;tJ;  
B /? L$m  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ sp9gz~Kq  
y_]+;%w:  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? eL!41_QI  
~/ %Xm<  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ =bVPHrKNQ  
2z.ot'  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© {pzj@b 1S  
s}D>.9  
1. Fas(CD95)/FasL yU$ MB,1  
/r}L_w I  
2. common chain of cytokine receptor )8Va%{j  
WWT1= #"  
3 . TCR/CD3 complex b}J%4Lx%m  
3Ob.OwA  
4. negaive selection of thymocytes ~z,o):q1 }  
)P$(]{  
5. artificial active immune &W `xZyb3  
^;C&  
6. anti-idiotypic | HazM9=  
n*4`Tduu^  
7. IgSF 2*Z2uV^  
h}b:-a  
8. Integrin O5\r%&$xd  
LQ0/oYmNc  
9. chemokine OvdT* g=8*  
UD I{4+z  
10. B7/CD28 sFU< PgV  
qsj{0Go  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© =8^+M1I  
7Z-j'pq  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ XTol|a=  
Uj@th  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ 6r7>nU&d  
'r;mm^cS?  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ dBWny&  
6Z\aJ  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ ;m/e|_4;y  
0.GFg${v`  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ 4;`z6\u9-  
 MlO OB  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ 1$E(8"l  
ttP7-y  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 5#Er& 6s  
X+vKY  
1. B7/CD28 'u,|*o  
|k a _Zy  
2. Th1 subset jP@ @<dt  
(* -wiL  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© \S}/2]* 1  
#~0N k6*u  
4. antibody affinity maturation p1N}2]e  
-jH|L{Iyq}  
5. AP-1 hgU;7R,?ir  
a~}q]o?j  
6. single chain variable fragment£¨ScFv£© hBgE%#`s  
i_qY=*a?y  
7. NK cell receptor ZmK=8iN9J  
;zCUx*{  
8. Zinkernagel-Doherty phenomenon n 0!8)Sth  
`46~j  
9. Ig fold 6w.E Sm  
}'[>~&/"  
10. CD40/CD40L ;i@S}LwL  
-^&=I3bp  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© "@ >6<(Ki  
=<]`'15"V  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ J4bP(=w!  
Emlj,c<? j  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ zlMh^+rMX  
^'3c%&Zf3  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ 9r%fBiSk  
G,C`+1$*  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ OP/DWf  
eV7;#w<]  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ Y?^liI`#  
"FHJ_$!  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ yr\ClIU  
TdFU,  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ sx?IIFF  
8eqTA8$?  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© 99yWUC,  
CL0 lMZ  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© ?/|Xie  
rHKO13WF  
1.Co-stimulators (or co-stimulating molecules) =lAjQt  
_[rFnyC+0V  
2.NK-kB  IuY9Q8  
U["0B8  
3.Immunoglobulin superfamily |z)s9B;:#i  
Y` }X5(A@  
4.antigen-presenting cell (APC) cWW?@ _  
oq7G=8gTp  
5.death domain fd[N]I3  
8-#kY}d.  
6.CCR and CXCR 1L,L/sOwB&  
NP;W=A F  
7.Lectin (or mitogen) ZR1U&<0c@  
44KoOY_  
8.Clusters of differentiation, CD) 4Y(@ KU b  
hywcj\[  
9.B7 family Zv!`R($  
u1meys a{0  
10.Cytotoxic T lymphocyte, CTL) vAX(3  
lcl|o3yQ  
11.IL-15 and IL-15 receptor (IL-15R)  GK/Po51  
j n^X{R\  
12.MHC restriction ET.jjV  
,D{7=mDVm  
13.Affinity-chromatography w(@r-2D"  
n^nE&'[?0g  
14.Cyctosprin A, CsA N,TV?Q5l7  
m?kiGC&m  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) %jHm9{|X  
dk&e EDvfd  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 2|;|C8C  
(H_dZL  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 m|q,i xg  
! VR&HEru  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ ,)`_?^ \$f  
IHTim T?  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ !R8%C!=a  
v_XN).f;  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© >W>rhxU  
C&z!="hMhR  
ÃâÒßѧרҵ£º JX0M3|I=  
W'4/cO  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ PIH\*2\/  
wlNL;W@w  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ SrKitSG  
)=f}vHg$  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿  u 8o!  
htB7 j(  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) VgbNZ{qk@  
U =J5lo  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) [+o{0o>  
Lip#uuuXXN  
1. ADCC(antibody dependent cell-mediated cytotoxicity) 8;g i8Y  
UIEvwQ  
2. »·æß¾úËØ(cyclosporin) a*(Zb|g  
?d%)R*3IX  
3. KIR(killer cell inhibitory receptor) d~8U1}dP  
9(]_so24,  
4. HLDA(human leucocyte differentiation antigen) _4>DuklH,  
+nR("Il  
5. Interleukin 18(IL-18) >Cr"q*  
}tt%J[  
6. ÕûºÏËØ(integrin) g/C 7wc  
eP~3m  
7. Fas/FasL :P q&l.  
x[t?hl=:  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) vGyQ306  
aX.BaK6I  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) F,_cci`p  
wA {) 9.  
10. Th1/Th2 L~ax`i1:"  
6Y[&1c8  
11. »ùÒòÒßÃç(DNAÒßÃç) ~"S5KroN  
!&OdbRHM  
12. chemokines and chemokine receptor ]yKwH 9sl  
s-*N_Dv  
13. ÃâÒßÄÍÊÜ Oi?Q^ISxP  
;s3@(OnjZ  
14. ¹²´Ì¼¤·Ö×Ó ^I/(9KP#  
;2h"YU-b  
15. ËÀÍö½á¹¹Óò(death domain) ?bd!JW bg`  
3=]/+{B  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) {;bec%pq0  
[ 2@Lc3<  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? 6Hc25NuQZ  
L,_U co  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ&>B |?d  
_)-2h[  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î b <fN,U< k  
j5Yli6r?3-  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ RW>F %P  
rGH7S!\AM  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå unL1/JY z  
9LQy 0Gx  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ 5}N O~Xd<  
17Q* <iCs  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) !oV'  
!x:w2  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ [0+5 Gx  
,Ur~DXY  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ RDG,f/L2  
8DrKq]&  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»